{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:22:32Z","timestamp":1790871752420,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"DOI":"10.7759\/cureus.96824","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:04:12Z","timestamp":1763125452000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Molecular and Immune Biomarkers in Predicting Bladder Cancer Recurrence and Survival: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Saad","family":"Masood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch J","year":"2021","unstructured":"Dobruch J, Oszczud\u0142owski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021, 57:9. 10.3390\/medicina57080749","journal-title":"Medicina (Kaunas)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205019","article-title":"Predicting recurrence of non-muscle-invasive bladder cancer: current techniques and future trends","volume":"14","author":"Shalata AT","year":"2022","unstructured":"Shalata AT, Shehata M, Van Bogaert E, et al.. Predicting recurrence of non-muscle-invasive bladder cancer: current techniques and future trends. Cancers (Basel). 2022, 14:9. 10.3390\/cancers14205019","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61010153","article-title":"Enhancing therapy adherence: impact on clinical outcomes, healthcare costs, and patient quality of life","volume":"61","author":"Religioni U","year":"2025","unstructured":"Religioni U, Barrios-Rodr\u00edguez R, Requena P, Borowska M, Ostrowski J. Enhancing therapy adherence: impact on clinical outcomes, healthcare costs, and patient quality of life. Medicina (Kaunas). 2025, 61:3. 10.3390\/medicina61010153","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14273-y","article-title":"Novel gene expression-based risk stratification tool predicts recurrence in non-muscle invasive bladder cancer","volume":"25","author":"N S","year":"2025","unstructured":"N S, Ps H, P R, et al.. Novel gene expression-based risk stratification tool predicts recurrence in non-muscle invasive bladder cancer. BMC Cancer. 2025, 25:916. 10.1186\/s12885-025-14273-y","journal-title":"BMC Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055155","article-title":"Biomarkers for predicting bladder cancer therapy response","volume":"33","author":"Mihai IM","year":"2025","unstructured":"Mihai IM, Wang G. Biomarkers for predicting bladder cancer therapy response. Oncol Res. 2025, 33:533-47. 10.32604\/or.2024.055155","journal-title":"Oncol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1453278","article-title":"Bladder cancer biomarkers: current approaches and future directions","volume":"14","author":"Ahangar M","year":"2024","unstructured":"Ahangar M, Mahjoubi F, Mowla SJ. Bladder cancer biomarkers: current approaches and future directions. Front Oncol. 2024, 14:1453278. 10.3389\/fonc.2024.1453278","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100347","article-title":"Unveiling the link between chronic inflammation and cancer","volume":"25","author":"Tripathi S","year":"2025","unstructured":"Tripathi S, Sharma Y, Kumar D. Unveiling the link between chronic inflammation and cancer. Metabol Open. 2025, 25:100347. 10.1016\/j.metop.2025.100347","journal-title":"Metabol Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-019-0050-0","article-title":"Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement","volume":"3","author":"Grooten WJ","year":"2019","unstructured":"Grooten WJ, Tseli E, \u00c4ng BO, Boersma K, St\u00e5lnacke BM, Gerdle B, Enthoven P. Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement. Diagn Progn Res. 2019, 3:5. 10.1186\/s41512-019-0050-0","journal-title":"Diagn Progn Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff RF","year":"2019","unstructured":"Wolff RF, Moons KG, Riley RD, et al.. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019, 170:51-8. 10.7326\/M18-1376","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting PF","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, et al.. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155:529-36. 10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados B","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, et al.. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022, 82:212-22. 10.1016\/j.eururo.2022.04.013","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig TW","year":"2023","unstructured":"Flaig TW, Tangen CM, Daneshmand S, et al.. Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695). Eur Urol. 2023, 84:341-7. 10.1016\/j.eururo.2023.06.014","journal-title":"Eur Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15379","article-title":"A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma","volume":"129","author":"Schuettfort VM","year":"2022","unstructured":"Schuettfort VM, D'Andrea D, Quhal F, et al.. A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU Int. 2022, 129:182-93. 10.1111\/bju.15379","journal-title":"BJU Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes JA","year":"2018","unstructured":"Witjes JA, Morote J, Cornel EB, et al.. Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol. 2018, 1:307-13. 10.1016\/j.euo.2018.06.011","journal-title":"Eur Urol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85188-4","article-title":"Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers","volume":"11","author":"Al-Saraireh YM","year":"2021","unstructured":"Al-Saraireh YM, Alshammari FO, Youssef AM, et al.. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021, 11:5581. 10.1038\/s41598-021-85188-4","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1801755","article-title":"Current issues of next-generation sequencing-based circulating tumor DNA analysis in colorectal cancer","volume":"13","author":"Rathnasamy N","year":"2024","unstructured":"Rathnasamy N, Lavingia V, Aggarwal S, et al.. Current issues of next-generation sequencing-based circulating tumor DNA analysis in colorectal cancer. South Asian J Cancer. 2024, 13:241-5. 10.1055\/s-0044-1801755","journal-title":"South Asian J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li L","year":"2024","unstructured":"Li L, Sun Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm (2020). 2024, 5:e766. 10.1002\/mco2.766","journal-title":"MedComm (2020)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13100312","article-title":"Real-world technical hurdles of ctDNA NGS analysis: lessons from clinical implementation","volume":"13","author":"Cabello-Aguilar S","year":"2025","unstructured":"Cabello-Aguilar S, Vendrell JA, Solassol J. Real-world technical hurdles of ctDNA NGS analysis: lessons from clinical implementation. Diseases. 2025, 13:2. 10.3390\/diseases13100312","journal-title":"Diseases"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01884-2","article-title":"Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective","volume":"17","author":"Lavoro A","year":"2025","unstructured":"Lavoro A, Ricci D, Gattuso G, et al.. Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective. Clin Epigenetics. 2025, 17:76. 10.1186\/s13148-025-01884-2","journal-title":"Clin Epigenetics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D'Andrea D","year":"2019","unstructured":"D'Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, Shariat SF. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019, 123:959-67. 10.1111\/bju.14673","journal-title":"BJU Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.128","article-title":"Precision oncology clinical trials: a systematic review of phase II clinical trials with biomarker-driven, adaptive design","volume":"56","author":"Ha H","year":"2024","unstructured":"Ha H, Lee HY, Kim JH, et al.. Precision oncology clinical trials: a systematic review of phase II clinical trials with biomarker-driven, adaptive design. Cancer Res Treat. 2024, 56:991-1013. 10.4143\/crt.2024.128","journal-title":"Cancer Res Treat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612613","article-title":"The future of precision oncology","volume":"24","author":"Rulten SL","year":"2023","unstructured":"Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJ. The future of precision oncology. Int J Mol Sci. 2023, 24:3. 10.3390\/ijms241612613","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432518-evaluating-molecular-and-immune-biomarkers-in-predicting-bladder-cancer-recurrence-and-survival-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:04:13Z","timestamp":1763125453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432518-evaluating-molecular-and-immune-biomarkers-in-predicting-bladder-cancer-recurrence-and-survival-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.96824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}